Published Research Summaries (click "Search" in Menu to filter)

Rheumatoid arthritis patients who use cannabis have lower chances of depression, chronic pain, and anxiety

The data came from the NIS (National Inpatient Sample) database of hospital visits maintained by the Agency for Healthcare Research and Quality. Over 3.3 million Rheumatoid Arthritis patients from 2016 to 2021 were included.

Parkinson's non-motor symptoms reduced with microdoses of THC and CBD

Non-motor Parkinson's Disease symptoms can include cognitive impairment, sleep disturbances, autonomic dysfunction, anxiety and depression. It was published in the journal Frontiers in Human Neuroscience in February 2025.

Study: Medicinal cannabis can be more effective than opioids for pain in some patients

"Medical marijuana was comparatively more effective than prescription medications for the treatment of chronic pain at 3 months"

Children with rare epilepsies continue to respond to CBD

This program allowed children with certain types of epilepsy to be treated with purified cannabidiol, in the form of an approved CBD isolate, since standard treatments were ineffective. It was published in March 2025 in Epilepsy and Behavior Reports.

UK cancer patients say cannabis helps them manage pain

This study examined cannabis-based medicinal products' effectiveness in relieving pain specifically experienced by cancer patients. It was published in February 2025 in the Journal of Pain & Palliative Care Pharmacotherapy.

Bioavailability of CBD can be over 50%, but as low as 4%

"the oral bioavailability can significantly vary based on the food intake, with a high-fat meal increasing the maximum concentration by fivefold." Also, vaporized CBD isolate had a much lower bioavailability than did CBD hemp flower.

CBD isolate shows effectiveness for dental pain

This is a randomized, placebo-controlled, triple-arm, phase IIA clinical trial that investigated the effectiveness and safety of CBD for acute dental pain. It was published in the journal Evidence-Based Dentistry in April 2024.

Migraines and vaporized cannabis flower: a placebo-controlled, randomized trial

71 migraine patients tested up to 4 different types of cannabis flower, each with a different THC/CBD ratio. The average age was 41 and they were mostly female (83%).

Clinical outcomes of osteoarthritis patients using cannabinoid medicine

Osteoarthritis patients with chronic pain who were prescribed cannabis-based medicinal products in the UK reported their outcomes over 12 months. The study was published in April 2024 in the Journal of Pain & Palliative Care Pharmacotherapy.

CBD and Caryophyllene combined reduce inflammation markers better than each alone

Published in the journal Pharmaceuticals (Basel) in April 2024, this study focused on dermatological anti-inflammatory effects of CBD and/or beta-caryophyllene in vitro in a model of human skin inflammation.

High fat meals dramatically increase CBG bioavailability

This small double-crossover pilot study examined the bioavailability of CBG isolate and a type of CBG emulsion administered orally with different meals. It was published online ahead of print in Cannabis and Cannabinoid Research in April 2024.

Study shows synthetic THC is effective for non-movement Parkinson's Disease symptoms

This small open-label study examined the effects of synthetic THC on non-movement symptoms, or NMS (primarily sleep and pain) in long-term Parkinson's patients. It was published in the journal NPJ Parkinson's Disease in March 2024.

Mayo Clinic fibromyalgia patients say cannabis is effective for symptom relief

1336 patients with an average age of 48 were included in this cross-sectional study. Most identified as female and just under half reported using cannabis to help manage their symptoms.

Traumatic Brain Injury outcomes after recreational cannabis use

"This study adds evidence about the potentially neuroprotective effects of recreational cannabis for short- and long-term post-TBI outcomes." It was published in April 2024 in the journal Neuropsychiatric Disease and Treatment.

CBD reduces TMJ disorder symptoms

This double-blind, placebo controlled study examined the effects of CBD on the symptoms of temporomandibular joint (jaw) disorders. It was published in the Journal of Clinical Medicine in March 2024.

Clinical Trial Review: CBD use in pediatric patients with Dravet Syndrome

"This review consolidates evidence from multiple clinical trials, affirming the potential of CBD as a promising treatment option for pediatric patients with DS." It was published in March 2024 in the European Journal of Medical Research.

Review study concludes CBD is effective as an anti-seizure medication

"Rigorous studies reveal CBD’s robust efficacy in diverse epileptic encephalopathies, with real-world data supporting significant seizure reductions." It was published in the Expert Opinion on Drug Metabolism and Toxicology in March 2024.

Patients say cannabis is effective, but strains don't seem to matter

Just over 1,000 patients who were prescribed medical cannabis and supervised by a physician in Germany in June, July, and August 2020, were included. Around 60% of the patients had been using MC for more than a year.

1 2 3 … 21

ads:

Your cart is currently empty.

Enable cookies to use the shopping cart

t: e

(-)

Item Quantity

Special instructions